Among shared targets, we identify <i>PARP11/Parp11</i> as a consistently up-regulated gene in glioma, which is down-regulated after MIRO1-binding compound treatment in both human and mouse gliomas. The gene discussed is PARP11; the disease is central nervous system cancer.